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OBJECTIVE— To assess the efficacy of Sativex, a cannabis-based medicinal extract, as ad-
juvant treatment in painful diabetic peripheral neuropathy (DPN).
RESEARCH DESIGN ANDMETHODS— In this randomized controlled trial, 30 sub-
jects with painful DPN received daily Sativex or placebo. The primary outcome measure was
change in mean daily pain scores, and secondary outcome measures included quality-of-life
assessments.
RESULTS— There was significant improvement in pain scores in both groups, but mean
change between groups was not significant. There were no significant differences in secondary
outcome measures. Patients with depression had significantly greater baseline pain scores that
improved regardless of intervention.
CONCLUSIONS— This first-ever trial assessing the efficacy of cannabis has shown it to be
no more efficacious than placebo in painful DPN. Depression was a major confounder and may
have important implications for future trials on painful DPN.
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P ainful diabetic peripheral neuropa-thy (DPN) is a common and dis-tressing complication of diabetes
(1). Unfortunately, drug treatments are
often ineffective and complicated by un-
wanted side effects. Thus, there is need
for better treatment. We report the first
randomized placebo-controlled trial as-
sessing the efficacy and safety of a canna-
bis-based medicinal extract (Sativex) in
intractable painful DPN.
RESEARCH DESIGN AND
METHODS— A total of 38 patients
with chronic painful DPN (Neuropathy
Total Symptom Score 6 [2]4 and16)
for at least 6 months with stable glycemic
control (A1C 11%) were assessed.
Those with persistent pain, despite an ad-
equate trial of tricyclic antidepressants,
were recruited. All patients gave written
informed consent. The study had Shef-
field Ethics Committee approval.
A prospective randomized double-
blind placebo-controlled trial design was
used. Baseline pain scores were obtained
prerandomization. Three modalities of
pain (superficial, deep, and muscular
pain) were assessed daily using a 100-mm
visual analog scale (VAS). The dose of
study medication was titrated over 2
weeks, followed by a 10-week mainte-
nance phase. At baseline, depression was
assessed using the seven-item depression
subscale of the Hospital Anxiety and De-
pression Scale (HADS-D) (3). Patients
continued preexisting neuropathic pain
treatment during the study.
Improvement in pain, as assessed by
the pain diary and Neuropathic Pain Scale
(NPS [4]) questionnaire, was used as the
primary outcome measure. Study end
point was the final week mean pain and
NPS score while taking the maximum tol-
erated dose of study medication. A total
pain score (TPS) (average score of all three
pain modalities) was also calculated. Sec-
ondary outcome measure was quality of
life (QOL), assessed by McGill Pain and
QOL (5), SF-36 Health Survey (6), and
EuroQOL (7) questionnaires. Tolerability
and side effects were evaluated using stan-
dardized forms.
Sativex (tetrahydrocannabinol [27
mg/ml] and cannabidiol [25 mg/ml]) and
its matching placebo were presented as a
pump-action spray. Doses were adminis-
tered sublingually in divided doses up to
four times a day.
Statistical analysis
An intent-to-treat analysis was under-
taken. Differences in subgroup baseline
characteristics were correlated to the
outcome and adjustments performed at
a coefficient 0.50. The distributions
of outcome measures with each of the
covariates were analyzed. Multiple lin-
ear regression was used for a normal
distribution, while skewed distribution
was initially transformed. Data on pro-
portions was analyzed using Fisher’s ex-
act test.
In a post hoc analysis, patients were
divided into individuals with depression
(HADS-D score 10) and no depression
(HADS-D score 10). Using ANCOVA,
we compared mean change in TPS from
baseline between these groups. The inter-
action between depression and treatment
was assessed using two-factor ANOVA.
Each treatment arm was divided into pa-
tients with and without depression, and
outcomes were compared using an inde-
pendent sample t test.
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RESULTS— Of 30 patients random-
ized, 6 withdrew because of adverse
events. We excluded one placebo-treated
patient from the intent-to-treat analysis
(n  29) because of a protocol violation.
Primary outcome measure
Covariates used in the analysis were du-
ration of diabetes, baseline scores, age,
and sex. There was no significant differ-
ence in mean change TPS between Sativex
and placebo (P 0.40; SEM 9.5; 95% CI
11.3 to 27.8) at end point. Similarly,
there was no difference in mean change in
superficial (P  0.72; 9.1; 15.3 to
21.93), deep (P  0.38; 10.5; 12.2 to
30.8), and muscular (P  0.26; 10.3;
9.15 to 33.0) pain VAS. Differences in
NPS did not reach statistical significance
(P  0.62; 7.8; 20.1 to 12.1).
Eight (53%) Sativex-treated patients
responded (defined as 30% total pain
VAS improvement) versus nine (64%)
placebo patients (P  0.55, odds ratio
0.63, 95% CI 0.14–2.82) (Table 1).
Secondary outcome measures
The McGill pain questionnaire showed no
difference in sensory scale (P  0.65;
SEM 3.3; 95% CI 5.39 to 8.44), affec-
tive scale (P  0.81; 1.3; 3.0 to 2.4),
VAS (P  0.24; 1.0; 0.91 to 3.4), and
present pain intensity (P  0.57; 0.53;
0.79 to 1.4) between study cohorts.
EuroQOL and SF-36 questionnaires showed
improvement in both groups, but differ-
ences between groups were not statisti-
cally significant (Table 1).
Post hoc analysis
We excluded one patient (Sativex) be-
cause baseline HADS-D was incomplete.
Mean HADS-D for patients with depres-
sion (n 10) and no depression (n 18)
were 13.4  3.5 (means  SD) and
5.94 2.2, respectively. Patients with de-
pression had significantly higher baseline
TPS (62.3  22.1 vs. 43.4  24.3; P 
0.05) and greater TPS improvement
(31.6  24.2 vs. 10.7  25.0; P 
0.04, SEM 9.8, 95% CI 0.54–41.1) com-
pared with those without depression.
There was no significant interaction be-
tween treatment group and depression.
However, there was a significant main ef-
fect of depression on TPS (P 0.05), sug-
gesting that in both treatment arms,
patients who were depressed were more
likely to respond to intervention: Sativex
arm, depressed (36.7  28.6) vs. non-
depressed (4.9  14.4), P  0.02,
56.5 to 7.2; placebo arm, 26.5 
20.7 vs.17.3 33.1, P 0.60,45.9
to 27.6.
CONCLUSIONS— Despite being
common, there are few effective treat-
ments that provide symptomatic relief for
painful DPN (8). For centuries, cannabi-
noids have been consumed for their anal-
gesic properties and more recently
studied in other neuropathic conditions
(9). In this study, when compared with
placebo, Sativex failed to show statisti-
cally significant improvements in primary
and secondary outcome measures. De-
pression was identified as a major con-
founder of study outcome. Patients with
depression had higher baseline pain
scores and were also more likely to re-
spond favorably to intervention, regard-
less if Sativex or placebo.
Most painful DPN trials to date either
have not screened for depression or ex-
clude individuals who have it (10,11).
This study demonstrates that depression
is potentially a major confounder in
chronic pain trials. Future trials should
consider screening for depression before
recruiting patients.
As in a number of recent studies,
there was a large placebo effect that may
have led to a failure to show differences in
outcome measures (12). This may pro-
vide an insight into the nature of pain in
DPN and the placebo effect. There is a need
for more robust and objective end points
for use in clinical trials of painful DPN.
Use of concomitant medications may
be a confounding factor. They were con-
Table 1 —Demographics and primary and secondary outcome measures
Baseline End point
PSativex Placebo Sativex Placebo
Age (years) 58.2  8.8 54.4  11.6 0.24
Sex (female) 4 7 0.38
BMI (kg/m2) 31.9  6.3 31.6  8.2 0.92
Cannabis (previous use) 2 0 0.60
A1C (%) 8.64  1.7 8.39  1.6 0.72
Diabetes duration (years) 11.2  8.4 13.7  6.0 0.37
Type of diabetes (type 2) 13 11 0.23
Study medication amount
(ml) 0.70  0.38 0.73  0.38 0.84
Pain diary scores
Superficial pain 52.3  33.0 45.9  24.6 37.9  32.1 30.2  30.1 0.72
Deep pain 63.1  29.4 47.4  21.4 44.5  32.7 24.9  29.5 0.38
Muscular pain 52.0  34.2 41.4  28.3 37.9  32.9 20.4  29.9 0.26
TPS 55.8  26.7 44.9  21.5 40.1  28.5 25.2  28.8 0.40
Neuropathic pain scale
Total score 67.1  19.4 63.6  14.0 51.6  21.9 51.9  24.1 0.62
McGill pain questionnaire
Sensory scale 19.2  6.9 16.3  6.3 14.7  7.2 12.5  8.7 0.65
Affective scale 4.6  4.3 5.0  3.8 3.1  2.3 3.6  3.8 0.81
VAS 7.6  1.8 6.9  1.7 5.1  2.2 3.8  2.6 0.24
Present pain intensity 2.5  1.1 2.0  1.0 2.1  1.1 1.4  1.7 0.57
EQ-5D questionnaire
Health status index 0.40  0.21 0.43  0.21 0.54  0.22 0.6  0.2 0.87
Health status VAS 46.0  20.4 44.6  21.8 58.1  20.5 56.4  11.7 0.92
SF-36 questionnaire
Physical functioning 26.9  15.1 30.8  22.7 30.5  16.6 36.5  27.9 0.63
Role physical 8.9  27.1 12.5  23.5 12.5  32.1 39.3  47.7 0.12
Bodily pain 22.4  15.5 25.7  11.3 35.6  16.6 41.2  24.6 0.64
General health 33.5  18.7 28.4  20.8 34.1  18.2 29.6  19.5 0.78
Vitality 28.3  23.2 30.8  19.2 33.9  22.4 39.6  19.4 0.45
Social functioning 50.8  32.5 48.2  24.9 55.4  25.3 67.0  27.6 0.08
Role emotional 38.1  41.1 33.3  40.8 54.8  46.4 47.6  48.4 0.76
Mental health 57.9  22.6 57.1  19.9 64.4  20.3 59.4  20.6 0.76
Data are n or means SD unless otherwise indicated. Pain diary scores derived from 100 mm VAS completed
daily. TPS derived from average of superficial, deep, and muscular pain scores. EQ-5D, EuroQOL quality-
of-life questionnaire.
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tinued because Sativex was proposed for
adjunctive use in painful DPN. Also, it
was felt ethically inappropriate to discon-
tinue treatments from which patients may
be benefiting. This may have attenuated
the analgesic response to Sativex. The use
of specific painful DPN QOL question-
naires (13) may have captured subtle
changes missed by the generic ones used
in this study.
Finally, while the search for therapeu-
tic agents to halt or reverse the neuro-
pathic process continues, more effective
treatments are required that provide bet-
ter symptom control with fewer side ef-
fects. The assessment of depression may
be important when designing future clin-
ical trials into painful DPN.
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